About Atopic Dermatitis


  • Atopic dermatitis (AD) is a chronic inflammatory disease of the skin. It affects around 15-20% of children and 1-3% of adults. Almost 19% of children do not respond to current treatments. According to WHO the Quality of Life (QoL) impacts on children with Atopic Dermatitis are second only to Cerebral Palsy amongst childhood disorders.
  • Atopic Dermatitis happens when the body loses control over the Innate Immune System, an ancient immune mechanism design to protect our skin from bacterial and parasitic attacks.
  • ILC Therapeutics™ have developed and patented a number of synthetic peptides shown to powerfully modulate the key cells involved in Atopic Dermatitis. 
  • Our research and drug candidates represent a paradigm shift in Atopic Dermatitis treatment modulating the very earliest parts of the ongoing immune response. An analogy would be : putting out the camp fires before they spread and become  significant  life changing forest fires.

Basophils, Eosinophils & ILC 2 Effects

 

  • Our lead peptide ILCT 1001 has been shown to:
  • Significantly downregulate (x100’s fold) the expression of IgE receptors on Basophils.
  • Reduce the production of IL-5 an Eosinophil growth factor and key player in allergic reactions.
  • Reduce IL-4 production an Eosinophil attractant.
  • Reduce IL-13 production.